JPH07206472A - Borosilicate glass for medicine - Google Patents
Borosilicate glass for medicineInfo
- Publication number
- JPH07206472A JPH07206472A JP1482894A JP1482894A JPH07206472A JP H07206472 A JPH07206472 A JP H07206472A JP 1482894 A JP1482894 A JP 1482894A JP 1482894 A JP1482894 A JP 1482894A JP H07206472 A JPH07206472 A JP H07206472A
- Authority
- JP
- Japan
- Prior art keywords
- glass
- working point
- borosilicate glass
- thermal expansion
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/089—Glass compositions containing silica with 40% to 90% silica, by weight containing boron
- C03C3/091—Glass compositions containing silica with 40% to 90% silica, by weight containing boron containing aluminium
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は注射用アンプル、管瓶用
ガラス等に使用される無色透明な医薬用ホウケイ酸ガラ
スに関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a colorless and transparent pharmaceutical borosilicate glass used for injection ampoules, glass for tube bottles, and the like.
【０００２】[0002]
【従来の技術】注射用アンプルや管瓶用ガラスには、充
填される薬液を汚染しないように化学的耐久性が高いこ
とや、耐熱性を有するように低膨張であること等が要求
され、従来よりこのような条件を満たすものとして、Ｓ
ｉＯ2 −Ｂ2 Ｏ3 −Ａｌ2 Ｏ3−Ｎａ2 Ｏ−Ｋ2 Ｏ−Ｂ
ａＯ系等のホウケイ酸ガラスが知られている。2. Description of the Related Art Ampoule for injection and glass for tube bottle are required to have high chemical durability so as not to contaminate the drug solution to be filled and low expansion so as to have heat resistance. Conventionally, as a condition that satisfies such a condition, S
iO 2 -B 2 O 3 -Al 2 O 3 -Na 2 O-K 2 O-B
Borosilicate glass such as aO is known.
【０００３】ところで上記したようなＢａＯを含有する
ホウケイ酸ガラスは優れた化学的耐久性を有するもので
あるが、ガラス溶融時や成管時にＢａＯ成分とアルミナ
系耐火物との反応によってバリウム長石結晶が析出し易
く、生産歩留りが低い。また薬品中の硫酸イオンとガラ
ス中のＢａＯとが反応して沈殿物が生じる恐れがある。By the way, the borosilicate glass containing BaO as described above has excellent chemical durability, but the barium feldspar crystal is formed by the reaction between the BaO component and the alumina refractory during the glass melting or forming. Is easily deposited and the production yield is low. Further, sulfate ions in the chemicals may react with BaO in the glass to form a precipitate.
【０００４】このような事情から、ＢａＯを含有しない
医薬用ホウケイ酸ガラスが各種提案されている。例えば
本発明者の発明になる特開平４−７４７３１号にはＳｉ
Ｏ2−Ｂ2 Ｏ3 −Ａｌ2 Ｏ3 −Ｎａ2 Ｏ−Ｋ2 Ｏ−Ｃａ
Ｏ系のホウケイ酸ガラスが開示されている。Under these circumstances, various borosilicate glasses for medical use which do not contain BaO have been proposed. For example, in Japanese Patent Laid-Open No. 4-74731, which is the invention of the present inventor,
O 2 -B 2 O 3 -Al 2 O 3 -Na 2 O-K 2 O-Ca
O-based borosilicate glass is disclosed.
【０００５】[0005]
【発明が解決しようとする課題】しかしながら上記特開
平４−７４７３１号に開示のホウケイ酸ガラスは、作業
点が高い（１１６５℃以上）という欠点がある。即ち、
作業点が高いと、素材管からバーナー加工してアンプル
や管瓶等のガラス容器に成形する際の成形温度を高くせ
ざるを得ず、その結果ガラスからアルカリ成分が揮発し
て成形中のアンプルや管瓶の内面に焼き付いてしまう。
この焼き付いたアルカリ分は洗浄しても完全に除去する
ことができず、これが薬液の保存中や薬液充填後のオー
トクレーブ加熱で溶け出して薬液のｐＨを上げたり、薬
液を変質させたりする可能性がある。また成形時にアル
カリ成分が揮発すると、これが成形治具に付着して成形
不良を起こしたり、成形治具の寿命を縮める原因とな
る。However, the borosilicate glass disclosed in Japanese Unexamined Patent Publication (Kokai) No. 4-74731 has a drawback that the working point is high (1165 ° C. or higher). That is,
If the working point is high, it is necessary to raise the molding temperature when the material tube is burner processed into glass containers such as ampoules and tube bottles, and as a result, the alkaline component volatilizes from the glass and the ampoule being molded. And the inside of the tube bottle will be burned.
This burned alkaline component cannot be completely removed even by washing, and it may melt during storage of the chemical solution or heating in an autoclave after filling the chemical solution to raise the pH of the chemical solution or change the quality of the chemical solution. There is. Further, when the alkaline component volatilizes during molding, it adheres to the molding jig and causes defective molding, or shortens the life of the molding jig.
【０００６】本発明の目的は、要求される諸特性を満足
し、しかも低い作業点を有する無色透明な医薬用ホウケ
イ酸ガラスを提供することである。An object of the present invention is to provide a colorless and transparent pharmaceutical borosilicate glass which satisfies the required properties and has a low working point.
【０００７】[0007]
【課題を解決するための手段】本発明者は種々の研究を
行った結果、構成成分をＳｉＯ2 、Ｂ2 Ｏ3 、Ａｌ2Ｏ3
、Ｎａ2 Ｏ、Ｋ2 Ｏ、ＣａＯ及び清澄剤のみに制限
し、且つこれらの成分の割合を厳密に限定することによ
り、上記目的が達成できることを見いだし、本発明とし
て提案するものである。As a result of various studies, the present inventor has found that the constituents are SiO 2 , B 2 O 3 , and Al 2 O 3.
It was found that the above object can be achieved by restricting only Na, Na 2 O, K 2 O, CaO and a fining agent and strictly limiting the proportions of these components, and it is proposed as the present invention.
【０００８】即ち、本発明の医薬用ホウケイ酸ガラス
は、本質的にＳｉＯ2 、Ｂ2 Ｏ3 、Ａｌ2 Ｏ3 、Ｎａ2
Ｏ、Ｋ2 Ｏ、ＣａＯ及び清澄剤のみからなり、前記各成
分の割合が重量百分率でＳｉＯ2 ７０．０〜７５．０
％、Ｂ2 Ｏ3 １２．１〜１５．０％、Ａｌ2Ｏ3 ３．０
〜４．９％、Ｎａ2 Ｏ５．５〜７．５％、Ｋ2 Ｏ０．５
〜２．５％、ＣａＯ０．１〜１．０％、清澄剤０．０１
〜０．５％であり、３０〜３８０℃における熱膨張係数
が４６〜５２×１０-7／℃、作業点が１１４０℃以下、
第１２改正日本薬局方 注射剤用ガラス容器試験法 ア
ルカリ溶出試験第１法に基づくアルカリ溶出量が０．３
０ｍｌ以下であることを特徴とする。That is, the medicinal borosilicate glass of the present invention is essentially composed of SiO 2 , B 2 O 3 , Al 2 O 3 and Na 2.
O, K 2 O, CaO and a fining agent only, and the ratio of each of the above components is SiO 2 70.0 to 75.0 in weight percentage.
%, B 2 O 3 12.1-15.0%, Al 2 O 3 3.0
~4.9%, Na 2 O5.5~7.5%, K 2 O0.5
~ 2.5%, CaO 0.1-1.0%, fining agent 0.01
Is 0.5%, the thermal expansion coefficient at 30 to 380 ° C. is 46 to 52 × 10 −7 / ° C., the working point is 1140 ° C. or less,
12th revision Japanese Pharmacopoeia Glass container test method for injections Alkali elution test
It is characterized by being 0 ml or less.
【０００９】[0009]
【作用】本発明の医薬用ホウケイ酸ガラスは、本質的に
ＳｉＯ2 、Ｂ2 Ｏ3 、Ａｌ2 Ｏ3 、Ｎａ2 Ｏ、Ｋ2 Ｏ、
ＣａＯ及び清澄剤のみからなる。なおこれら以外の成分
が含まれると所望の特性が得られなくなり好ましくな
い。例えばＢａＯの添加は前述のように生産歩留りの低
下等を招き、またＺｒＯ2 を添加するとガラスの粘性が
増大し、結果的にアルカリ溶出量が多くなってしまう。The medicinal borosilicate glass of the present invention is essentially composed of SiO 2 , B 2 O 3 , Al 2 O 3 , Na 2 O, K 2 O,
Consists of CaO and fining agent only. If components other than these are contained, desired characteristics cannot be obtained, which is not preferable. For example, the addition of BaO causes a decrease in production yield as described above, and the addition of ZrO 2 increases the viscosity of glass, resulting in a large amount of alkali elution.
【００１０】次に各成分の組成範囲を上記のように限定
した理由を述べる。Next, the reason why the composition range of each component is limited as described above will be described.
【００１１】Ｓｉ０2 は主要なガラス形成酸化物であ
り、その含有量は７０．０〜７５．０％、好ましくは７
２．５〜７４．５％である。ＳｉＯ2 が７５．０％より
多いとガラスの溶融性及び成形性が著しく悪くなり、一
方７０．０％より少なくなると熱膨張係数が大きくなり
過ぎて耐熱性が悪くなり、バーナー加工後に直ちに徐冷
しないと成形品が破損し易くなる。SiO 2 is the main glass-forming oxide, the content of which is 70.0 to 75.0%, preferably 7
It is 2.5 to 74.5%. If the SiO 2 content is more than 75.0%, the glass meltability and moldability will be significantly deteriorated, whereas if it is less than 70.0%, the thermal expansion coefficient will be too large and the heat resistance will be poor, and the glass will be annealed immediately after burner processing. Otherwise, the molded product will be easily damaged.
【００１２】Ｂ2 Ｏ3 はガラスの溶融性を向上させる成
分であり、その含有量は１２．１〜１５．０％、好まし
くは１２．２〜１４．０％である。Ｂ2 Ｏ3 が１５．０
％より多くなると化学的耐久性が悪くなり、一方１２．
１％より少ないと上記した効果が得られない。B 2 O 3 is a component that improves the meltability of glass, and its content is 12.1 to 15.0%, preferably 12.2 to 14.0%. B 2 O 3 is 15.0
%, The chemical durability deteriorates, while 12.
If it is less than 1%, the above effect cannot be obtained.
【００１３】Ａｌ2 Ｏ3 はガラスの失透を抑制し、また
化学的耐久性を向上させる成分であり、その含有量は
３．０〜４．９％、好ましくは３．８〜４．８％であ
る。Ａｌ2 Ｏ3 が４．９％より多いとガラスの高温粘性
が大きくなって作業点が高くなり、その結果、成形時に
アルカリ成分が揮発し易くなってしまう。またガラスの
溶融性が悪くなる。一方３．０％より少ないとガラスの
液相温度が高くなって溶融中に失透し易くなったり、ガ
ラスが分相し易くなる。Al 2 O 3 is a component that suppresses devitrification of glass and improves chemical durability, and the content thereof is 3.0 to 4.9%, preferably 3.8 to 4.8. %. If the Al 2 O 3 content is more than 4.9%, the high temperature viscosity of the glass becomes large and the working point becomes high, and as a result, the alkaline component tends to volatilize during molding. In addition, the meltability of the glass deteriorates. On the other hand, if it is less than 3.0%, the liquidus temperature of the glass becomes high and the glass is liable to devitrify during melting or the glass is likely to undergo phase separation.
【００１４】Ｎａ2 Ｏはガラスの溶融性を向上させる効
果があり、その含有量は５．５％〜７．５％、好ましく
は６．０〜７．５％である。Ｎａ2 Ｏが７．５％より多
くなると化学的耐久性が悪くなるとともに熱膨張係数が
大きくなって耐熱性が低下する。一方５．５％より少な
くなると上記効果が得られなくなる。Na 2 O has the effect of improving the meltability of the glass, and its content is 5.5% to 7.5%, preferably 6.0 to 7.5%. If the content of Na 2 O is more than 7.5%, the chemical durability becomes poor and the coefficient of thermal expansion becomes large to lower the heat resistance. On the other hand, if it is less than 5.5%, the above effect cannot be obtained.
【００１５】Ｋ2 Ｏは化学的耐久性を向上させるととも
に液相温度を下げる成分であり、その含有量は０．５〜
２．５％である。Ｋ2 Ｏが２．５％より多いとガラスの
粘性が高くなり過ぎる。逆に０．５％より少なくなると
上記した効果が得られなくなる。K 2 O is a component that improves the chemical durability and lowers the liquidus temperature, and the content thereof is 0.5-.
It is 2.5%. If K 2 O is more than 2.5%, the viscosity of the glass becomes too high. On the contrary, if it is less than 0.5%, the above effect cannot be obtained.
【００１６】なおＮａ2 ＯとＫ2 Ｏの合量は８．５％以
下であることが好ましい。即ち、これらの成分の合量が
８．５％を超えると熱膨張係数が高くなって耐熱性が低
下するとともに、アルカリ溶出量が多くなるためであ
る。The total amount of Na 2 O and K 2 O is preferably 8.5% or less. That is, when the total amount of these components exceeds 8.5%, the coefficient of thermal expansion becomes high, the heat resistance decreases, and the amount of alkali elution increases.
【００１７】ＣａＯはガラスの溶融性を向上させる働き
があり、その含有量は０．１〜１．０％である。ＣａＯ
が１．０％より多くなると化学的耐久性が悪くなり、逆
に０．１％より少ないと上記した効果が得られなくな
る。CaO has a function of improving the melting property of glass, and its content is 0.1 to 1.0%. CaO
If it is more than 1.0%, the chemical durability is deteriorated, and if it is less than 0.1%, the above effect cannot be obtained.
【００１８】清澄剤としては、Ａｓ2 Ｏ3 、Ｓｂ2 Ｏ
3 、ＮａＣｌ等の１種又は２種以上を０．０１〜０．５
％含有する。清澄剤が０．５％より多いとＡｓ、Ｓｂ、
Ｃｌ等の溶出量が増大したり、バーナー加工によりガラ
スが変色してしまうおそれがある。逆に０．０１％より
少ないと清澄効果がない。As the fining agent, As 2 O 3 and Sb 2 O
3 , 1, 2 or more such as NaCl 0.01-0.5
%contains. If the clarifying agent is more than 0.5%, As, Sb,
There is a possibility that the amount of Cl and the like eluted may increase or that the glass may be discolored by burner processing. On the contrary, if it is less than 0.01%, there is no fining effect.
【００１９】また本発明の医薬用ホウケイ酸ガラスは、
３０〜３８０℃における熱膨張係数が４６〜５２×１０
-7／℃、作業温度が１１４０℃以下であり、第１２改正
日本薬局方 注射剤用ガラス容器試験法 アルカリ溶出
試験第１法に基づくアルカリ溶出量が０．３０ｍｌ以下
であることを特徴とする。熱膨張係数がこの範囲より大
きくなると耐熱性が悪くなり、逆に小さくなるとワンポ
イントカットアンプルのカラーピグメントの接着性が低
下して剥離する恐れがある。作業点が１１４０℃より高
くなると成形時にアルカリ成分の揮発が著しくなり、ま
た成形治具が劣化し易くなる。またアルカリ溶出量が
０．３０ｍｌよりも大きくなると、上記アルカリ溶出試
験第１法の融封できる容器の規定に適合しないために注
射用アンプルや管瓶に使用できなくなる。Further, the pharmaceutical borosilicate glass of the present invention comprises:
Thermal expansion coefficient at 30 to 380 ° C. is 46 to 52 × 10
-7 / ° C, working temperature is 1140 ° C or lower, and the amount of alkaline elution is 0.30 ml or less based on the 12th revised Japanese Pharmacopoeia Test method for glass containers for injections . If the coefficient of thermal expansion is larger than this range, the heat resistance will be poor, and if it is smaller, the adhesiveness of the color pigment of the one-point cut ampoule will be reduced and peeling may occur. If the working point is higher than 1140 ° C., the volatilization of the alkaline component becomes remarkable during molding, and the molding jig is apt to deteriorate. If the amount of alkali elution is more than 0.30 ml, it cannot be used for injection ampoules and vials because it does not meet the regulation of the container capable of being fused and sealed in the above first method of alkali elution test.
【００２０】[0020]
【実施例】以下、実施例に基づいて本発明の医薬用ホウ
ケイ酸ガラスを説明する。EXAMPLES The pharmaceutical borosilicate glass of the present invention will be described below based on examples.
【００２１】表１は本発明の実施例（試料Ｎｏ．１〜
４）、表２は比較例（試料Ｎｏ．５〜８）のガラス組
成、熱膨張係数、作業点、ガラスのアルカリ溶出量、及
びバリウム長石の析出の有無をそれぞれ示している。Table 1 shows examples of the present invention (Sample Nos. 1 to 1).
4) and Table 2 show the glass composition, the coefficient of thermal expansion, the working point, the alkali elution amount of the glass, and the presence or absence of barium feldspar precipitation in Comparative Examples (Sample Nos. 5 to 8), respectively.
【００２２】[0022]
【表１】 [Table 1]
【００２３】[0023]
【表２】 [Table 2]
【００２４】表中の各試料は次のようにして調製した。
まず表の組成になるようにガラス原料を調合した後、白
金坩堝に入れ実験炉で１５５０℃−６時間の条件で溶融
した。次いで溶融ガラスを一旦板状に成形し、徐冷後、
各特性の測定に供するために必要な形状に成形した。な
おこのようにして得られた各試料は、何れも無色透明で
あった。Each sample in the table was prepared as follows.
First, glass raw materials were mixed so as to have the composition shown in the table, and then they were put into a platinum crucible and melted in an experimental furnace under the conditions of 1550 ° C. and 6 hours. Next, the molten glass is once formed into a plate shape, and after slowly cooling,
It was molded into a shape required for the measurement of each characteristic. Each of the samples thus obtained was colorless and transparent.
【００２５】表から明らかなように、本発明の実施例で
ある試料Ｎｏ．１〜４は、３０〜３８０℃における熱膨
張係数が４８〜５０×１０-7／℃、作業点が１１０８〜
１１２５℃であり、ガラスのアルカリ溶出量が０．１２
〜０．１５ｍｌであった。またバリウム長石の析出は認
められなかった。As is apparent from the table, the sample No. which is an example of the present invention. Nos. 1 to 4 have a thermal expansion coefficient of 48 to 50 × 10 −7 / ° C. at 30 to 380 ° C. and a working point of 1108 to
It is 1125 ° C, and the amount of alkali elution of glass is 0.12
Was ~ 0.15 ml. No precipitation of barium feldspar was observed.
【００２６】これに対して比較例である試料Ｎｏ．５
は、熱膨張係数が４７×１０-7／℃、ガラスのアルカリ
溶出量が０．１２ｍｌであり、バリウム長石の析出も認
められなかったが、作業点が１１８０℃と高かった。試
料Ｎｏ．６は熱膨張係数が４９×１０-7／℃、作業点が
１１２３℃、ガラスのアルカリ溶出量が０．１３ｍｌで
あったが、バリウム長石の析出が認められた。試料Ｎ
ｏ．７は、熱膨張係数が４７×１０-7／℃、ガラスのア
ルカリ溶出量が０．１０ｍｌであり、バリウム長石の析
出も認められなかったが、作業点が１１４５℃と高かっ
た。試料Ｎｏ．８は作業点が１１３０℃であり、バリウ
ム長石の析出も認められなかったが、熱膨張係数が３８
×１０-7／℃と低く、またガラスのアルカリ溶出量が
１．５０ｍｌと非常に多かった。On the other hand, sample No. which is a comparative example. 5
Had a thermal expansion coefficient of 47 × 10 −7 / ° C., an alkali elution amount of glass of 0.12 ml, and no precipitation of barium feldspar was observed, but the working point was high at 1180 ° C. Sample No. No. 6 had a coefficient of thermal expansion of 49 × 10 −7 / ° C., a working point of 1123 ° C., and an alkali elution amount of glass of 0.13 ml, but precipitation of barium feldspar was observed. Sample N
o. In No. 7, the coefficient of thermal expansion was 47 × 10 −7 / ° C., the amount of alkali elution of glass was 0.10 ml, and precipitation of barium feldspar was not observed, but the working point was high at 1145 ° C. Sample No. No. 8 had a working point of 1130 ° C. and precipitation of barium feldspar was not observed, but the thermal expansion coefficient was 38.
It was as low as × 10 -7 / ° C, and the amount of alkali elution of glass was 1.50 ml, which was very large.
【００２７】なお、熱膨張係数は直径５ｍｍ、長さ５０
ｍｍの棒状に成形した試料を用い、熱膨張計によって測
定した。作業点は高温粘度計にて求めた。ガラスのアル
カリ溶出量は、第１２改正日本薬局方 注射剤用ガラス
容器試験法 アルカリ溶出試験第１法に基づいて測定し
た。バリウム長石の析出の有無については、アルミナ系
耐火物ボートに塊状のガラス試料を入れ、箱形電気炉中
で１２５０℃で６時間加熱し、続いて１１００〜９００
℃の温度傾斜炉で７日間加熱した後、各温度域の部分を
薄片にし、偏光顕微鏡にて観察して評価した。The coefficient of thermal expansion is 5 mm in diameter and 50 in length.
Using a sample molded into a rod shape of mm, the measurement was performed by a thermal expansion meter. The working point was determined by a high temperature viscometer. The amount of alkali elution of glass was measured based on the 12th revision Japanese Pharmacopoeia, Glass container test method for injections, Alkali elution test method 1. Regarding the presence or absence of precipitation of barium feldspar, a lump glass sample was put into an alumina refractory boat and heated in a box electric furnace at 1250 ° C. for 6 hours, and then 1100 to 900.
After heating in a temperature gradient furnace at ℃ for 7 days, each temperature region was sliced and observed with a polarizing microscope for evaluation.
【００２８】[0028]
【発明の効果】以上説明したように、本発明の医薬用ホ
ウケイ酸ガラスは、化学的耐久性等の医薬用ガラスとし
て求められる諸特性を満足し、しかも作業温度が低いた
めにバーナー加工時のアルカリ成分の揮発がなく、注射
用アンプルや管瓶用ガラスとして好適である。As described above, the pharmaceutical borosilicate glass of the present invention satisfies various characteristics required as a pharmaceutical glass such as chemical durability and has a low working temperature. It is suitable for injection ampoules and glass for tube bottles because it does not volatilize alkaline components.
Claims (1)
3 、Ｎａ2 Ｏ、Ｋ2Ｏ、ＣａＯ及び清澄剤のみからな
り、前記各成分の割合が重量百分率でＳｉＯ2７０．０
〜７５．０％、Ｂ2 Ｏ3 １２．１〜１５．０％、Ａｌ2
Ｏ3 ３．０〜４．９％、Ｎａ2 Ｏ５．５〜７．５％、Ｋ
2 Ｏ０．５〜２．５％、ＣａＯ０．１〜１．０％、清澄
剤０．０１〜０．５％であり、３０〜３８０℃における
熱膨張係数が４６〜５２×１０-7／℃、作業点が１１４
０℃以下、第１２改正日本薬局方注射剤用ガラス容器試
験法 アルカリ溶出試験第１法に基づくアルカリ溶出量
が０．３０ｍｌ以下であることを特徴とする医薬用ホウ
ケイ酸ガラス。1. Essentially SiO 2 , B 2 O 3 , Al 2 O
3 , Na 2 O, K 2 O, CaO and a refining agent only, and the ratio of each component is SiO 2 70.0 in weight percentage.
~75.0%, B 2 O 3 12.1~15.0 %, Al 2
O 3 3.0 to 4.9%, Na 2 O 5.5 to 7.5%, K
2 O 0.5 to 2.5%, CaO 0.1 to 1.0%, a fining agent 0.01 to 0.5%, and a thermal expansion coefficient at 30 to 380 ° C. of 46 to 52 × 10 −7 / ° C. , The working point is 114
0 ° C or less, 12th revision Japanese Pharmacopoeia Glass container test method for injection Alkali elution test The alkali elution amount based on the first method is 0.30 ml or less, and a pharmaceutical borosilicate glass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1482894A JPH07206472A (en) | 1994-01-12 | 1994-01-12 | Borosilicate glass for medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1482894A JPH07206472A (en) | 1994-01-12 | 1994-01-12 | Borosilicate glass for medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07206472A true JPH07206472A (en) | 1995-08-08 |
Family
ID=11871908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1482894A Pending JPH07206472A (en) | 1994-01-12 | 1994-01-12 | Borosilicate glass for medicine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07206472A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3039484U (en) * | 1996-03-26 | 1997-07-22 | 富士男 藤川 | Handstand bottle and far infrared vine cap |
| JPH11347124A (en) * | 1998-03-13 | 1999-12-21 | Becton Dickinson Fr Sa | Syringe |
| EP1923359A1 (en) * | 2005-05-16 | 2008-05-21 | Nipro Corporation | Vials and processes for producing the same |
| CN101891381A (en) * | 2010-07-28 | 2010-11-24 | 济南力诺玻璃制品有限公司 | High borosilicate glass for storing frozen biological products and preparation method thereof |
| CN102515523A (en) * | 2011-12-29 | 2012-06-27 | 山东省药用玻璃股份有限公司 | Borosilicate glass sleeve for pen type syringe and preparation method of borosilicate glass sleeve |
| WO2014014003A1 (en) | 2012-07-18 | 2014-01-23 | 日本電気硝子株式会社 | Glass for pharmaceutical product container, pharmaceutical product container glass tube using same, method for manufacturing pharmaceutical product container, and pharmaceutical product container |
| JP2014015365A (en) * | 2012-07-11 | 2014-01-30 | Nippon Electric Glass Co Ltd | Glass for medicine container and glass tube using the same |
| EP2796431A1 (en) * | 2013-04-26 | 2014-10-29 | Schott AG | Borosilicate glass with improved hydrolytic resistance preferably for use in the pharmaceutical industry |
| JP2014224131A (en) * | 2007-07-13 | 2014-12-04 | 田辺三菱製薬株式会社 | Stable fat emulsion comprising prostaglandin e1 |
| JP2015098430A (en) * | 2013-09-02 | 2015-05-28 | 日本電気硝子株式会社 | Borosilicate glass for medicament container |
| WO2017038738A1 (en) * | 2015-09-03 | 2017-03-09 | 日本電気硝子株式会社 | Borosilicate glass for medicine containers, glass tube for medicine containers and method for producing medicine container |
| JP2017048091A (en) * | 2015-09-03 | 2017-03-09 | 日本電気硝子株式会社 | Borosilicate glass for pharmaceutical container |
| JP2017057096A (en) * | 2015-09-15 | 2017-03-23 | 日本電気硝子株式会社 | Glass tube for medical container |
| JP2017078003A (en) * | 2015-10-22 | 2017-04-27 | 日本電気硝子株式会社 | Glass tube for medicine containers, and method for producing the same |
| JP2022009932A (en) * | 2011-10-25 | 2022-01-14 | コーニング インコーポレイテッド | Glass compositions with improved chemical and mechanical durability |
| WO2023107300A1 (en) * | 2021-12-06 | 2023-06-15 | Corning Incorporated | Chemically durable borosilicate glass compositions for storing pharmaceutical compositions and articles formed therefrom |
-
1994
- 1994-01-12 JP JP1482894A patent/JPH07206472A/en active Pending
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3039484U (en) * | 1996-03-26 | 1997-07-22 | 富士男 藤川 | Handstand bottle and far infrared vine cap |
| JPH11347124A (en) * | 1998-03-13 | 1999-12-21 | Becton Dickinson Fr Sa | Syringe |
| EP1923359A1 (en) * | 2005-05-16 | 2008-05-21 | Nipro Corporation | Vials and processes for producing the same |
| JPWO2006123621A1 (en) * | 2005-05-16 | 2008-12-25 | ニプロ株式会社 | Vials and manufacturing method thereof |
| EP1923359A4 (en) * | 2005-05-16 | 2010-03-24 | Nipro Corp | Vials and processes for producing the same |
| US10894735B2 (en) | 2005-05-16 | 2021-01-19 | Nipro Corporation | Vial and method for producing the same |
| US9751795B2 (en) | 2005-05-16 | 2017-09-05 | Nipro Corporation | Vial and method for producing the same |
| EP2546205A1 (en) * | 2005-05-16 | 2013-01-16 | Nipro Corporation | Vial and method for producing the same |
| EP2546206A1 (en) * | 2005-05-16 | 2013-01-16 | Nipro Corporation | Vial and method for producing the same |
| CN102898006A (en) * | 2005-05-16 | 2013-01-30 | 尼普洛株式会社 | Vials and processes for producing the same |
| JP5239338B2 (en) * | 2005-05-16 | 2013-07-17 | ニプロ株式会社 | Vials and manufacturing method thereof |
| US9580349B2 (en) | 2005-05-16 | 2017-02-28 | Nipro Corporation | Vial and method for producing the same |
| US9010150B2 (en) | 2005-05-16 | 2015-04-21 | Nipro Corporation | Vial and method for producing the same |
| US8820119B2 (en) | 2005-05-16 | 2014-09-02 | Nipro Corporation | Vial and method for producing the same |
| JP2014224131A (en) * | 2007-07-13 | 2014-12-04 | 田辺三菱製薬株式会社 | Stable fat emulsion comprising prostaglandin e1 |
| JP5890599B2 (en) * | 2007-07-13 | 2016-03-22 | 田辺三菱製薬株式会社 | Stable fat emulsion containing prostaglandin E1 |
| CN101891381A (en) * | 2010-07-28 | 2010-11-24 | 济南力诺玻璃制品有限公司 | High borosilicate glass for storing frozen biological products and preparation method thereof |
| JP2022009932A (en) * | 2011-10-25 | 2022-01-14 | コーニング インコーポレイテッド | Glass compositions with improved chemical and mechanical durability |
| CN102515523A (en) * | 2011-12-29 | 2012-06-27 | 山东省药用玻璃股份有限公司 | Borosilicate glass sleeve for pen type syringe and preparation method of borosilicate glass sleeve |
| JP2014015365A (en) * | 2012-07-11 | 2014-01-30 | Nippon Electric Glass Co Ltd | Glass for medicine container and glass tube using the same |
| EP2876092A4 (en) * | 2012-07-18 | 2016-01-06 | Nippon Electric Glass Co | Glass for pharmaceutical product container, pharmaceutical product container glass tube using same, method for manufacturing pharmaceutical product container, and pharmaceutical product container |
| WO2014014003A1 (en) | 2012-07-18 | 2014-01-23 | 日本電気硝子株式会社 | Glass for pharmaceutical product container, pharmaceutical product container glass tube using same, method for manufacturing pharmaceutical product container, and pharmaceutical product container |
| EP2796431A1 (en) * | 2013-04-26 | 2014-10-29 | Schott AG | Borosilicate glass with improved hydrolytic resistance preferably for use in the pharmaceutical industry |
| CN110128011B (en) * | 2013-04-26 | 2021-06-01 | 肖特股份有限公司 | Borosilicate glass with improved hydrolysis resistance, preferably for use in the medical field |
| CN110128011A (en) * | 2013-04-26 | 2019-08-16 | 肖特股份有限公司 | It is preferred for the Pyrex of the hydrolytic resistance with improvement of field of medicaments |
| JP2014214084A (en) * | 2013-04-26 | 2014-11-17 | ショット アクチエンゲゼルシャフトＳｃｈｏｔｔ ＡＧ | Borosilicate glass having improved hydrolysis resistance suitable for use in pharmaceutical field |
| JP2018193297A (en) * | 2013-09-02 | 2018-12-06 | 日本電気硝子株式会社 | Borosilicate glass for medicament container |
| JP2015098430A (en) * | 2013-09-02 | 2015-05-28 | 日本電気硝子株式会社 | Borosilicate glass for medicament container |
| JP2017048091A (en) * | 2015-09-03 | 2017-03-09 | 日本電気硝子株式会社 | Borosilicate glass for pharmaceutical container |
| WO2017038738A1 (en) * | 2015-09-03 | 2017-03-09 | 日本電気硝子株式会社 | Borosilicate glass for medicine containers, glass tube for medicine containers and method for producing medicine container |
| JP2017057096A (en) * | 2015-09-15 | 2017-03-23 | 日本電気硝子株式会社 | Glass tube for medical container |
| JP2017078003A (en) * | 2015-10-22 | 2017-04-27 | 日本電気硝子株式会社 | Glass tube for medicine containers, and method for producing the same |
| WO2023107300A1 (en) * | 2021-12-06 | 2023-06-15 | Corning Incorporated | Chemically durable borosilicate glass compositions for storing pharmaceutical compositions and articles formed therefrom |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4065317A (en) | Novel glass compositions | |
| JP3260046B2 (en) | Optical glass | |
| EP3004005B1 (en) | Glass for pharmaceutical containers | |
| EP0024032B1 (en) | Phosphate glass compositions, and glass-ceramic materials, and methods of making the same | |
| KR100296471B1 (en) | Lead free glass for sealing | |
| JPH07206472A (en) | Borosilicate glass for medicine | |
| CN110255895B (en) | Alkali-containing borosilicate glass and preparation method thereof | |
| CN112694254A (en) | Medium borosilicate glass composition, medium borosilicate glass, and preparation method and application thereof | |
| JP3800443B2 (en) | Non-alkali glass substrate for display and method for producing the same | |
| JPH0723231B2 (en) | Optical and ophthalmic glass | |
| US3499776A (en) | Alkali metal borosilicate glass compositions containing zirconia | |
| JPH1059741A (en) | Non-alkali glass and its production | |
| CN113582538A (en) | Borosilicate glass composition, borosilicate glass, and preparation method and application thereof | |
| JPH10114538A (en) | Alkali-free glass and its production | |
| JP6075600B2 (en) | Glass for pharmaceutical containers and glass tube using the same | |
| EP0261819B1 (en) | Molybdenum sealing glasses | |
| JPWO2018225691A1 (en) | Method for producing colored glass for pharmaceutical container and colored glass for pharmaceutical container | |
| WO2020153294A1 (en) | Glass for medicine container, and glass tube for medicine container and medicine container using same | |
| JPWO2017115728A1 (en) | Method for producing aluminoborosilicate glass for pharmaceutical containers | |
| JP7118587B2 (en) | borosilicate glass for pharmaceutical containers | |
| WO2014069177A1 (en) | Medicinal glass and medicinal glass tube | |
| JPH0959037A (en) | Boro-silicate glass for medicine | |
| JP2608535B2 (en) | Amber colored borosilicate glass | |
| JPH0474731A (en) | Borosilicate glass medical use | |
| CN110510873B (en) | Borosilicate glass and preparation method thereof |